Head & Neck Cancers | Clinical

Further Research Needed to Support Use of Checkpoint Inhibitors in Locally Advanced HNSCC

May 06, 2021

Avelumab was explored in a clinical trial for the treatment of locally advanced head and neck squamous cell carcinoma, but more research is needed to position the agent and other checkpoint inhibitors in the treatment landscape, experts say.

Tipifarnib Elicits Encouraging Responses in Patients With Recurrent or Metastatic HNSCC

April 27, 2021

Results from the phase 2 study of farnesyltransferase inhibitor tipifarnib showed significant responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma and demonstrated that variant alle frequency could be a potential biomarker in this patient population.

Roundtable Discussion: Treating Radioiodine-Refractory Differentiated Thyroid Cancer

April 26, 2021

During a virtual Targeted Oncology Case-Based Roundtable event, Lori Wirth, MD, discussed the treatment patients with radioiodine-refractory differentiated thyroid cancer with a group of peers.

Addressing Unmet Needs for Head and Neck Cancer Awareness Month

April 21, 2021

Stuart J. Wong, MD, discussed the KEYNOTE-048 trial, advances in head and neck cancers, and current unmet needs in this patient population in an interview with Targeted Oncology.

GlaxoSmithKline Discontinues Feladilimab in Clinical Trials for Metastatic HNSCC

April 16, 2021

GlaxoSmithKline plc has announced that they will stop enrolling patients in the phase 2 INDUCE-3 and INDUCE-4 trials while simultaneously ending the use of feladilimab, originally GSK3359609, for the treatment of PD-L1-positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma after the recommendation of the Independent Data Monitoring Committee.

FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC

April 08, 2021

A Fast Track designation was granted by the FDA to the soluble LAG-3 protein, eftilagimod alpha for the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.

FDA Approves New Dose of Cetuximab for KRAS Wild-Type, EGFR Expressing mCRC or SCCHN

April 07, 2021

The FDA has approved a higher dose of cetuximab for the treatmen of patients with KRAS wild-type, EGFR-expressing metastatic colorectal cancer or squamous cell carcinoma of the head and neck.

Combining PD-1/PD-L1 Inhibitors and HPV Vaccines Holds Promise in HNSCC

April 05, 2021

Research on combination therapies involving human papillomavirus-targeted vaccines and immunotherapies continues to expand in phase 2 and 3 trials in patients with head and neck squamous cell carcinoma.

Translational Medicine Forges Ahead in HPV-Associated Cancers

April 03, 2021

Nearly 20% of the world’s cancer cases are caused by viruses, and 7 viruses have been documented to cause this aggregate number of cancer cases, with HPV being the most well recognized.

Outcomes Underscore Need for New Agents to Treat Anaplastic Thyroid Carcinoma

March 16, 2021

Christine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.